Lessons learned from variation in response to therapy in clinical trials

Area of Science:

• Pulmonology
• Clinical Pharmacology
• Personalized Medicine

Background:

• Previously, poor response to asthma medications was considered rare.
• Recent research indicates substantial variability in treatment response across all asthma medications.
• Predictive methods for favorable treatment response remain largely unexplored.

Purpose of the Study:

• To verify treatment response variability to long-term control medications in mild-to-moderate persistent asthma.
• To identify patient characteristics and biomarkers for predicting treatment response.
• To guide personalized asthma treatment selection.

Main Methods:

• Analysis of data from the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education Network.
• Evaluation of response to inhaled corticosteroids and leukotriene receptor antagonists.
• Assessment of patient characteristics (age, allergic status) and biomarkers (bronchodilator response, exhaled nitric oxide, urinary leukotrienes).

Main Results:

• Confirmed significant variability in response to inhaled corticosteroids and leukotriene receptor antagonists in adults and children.
• Identified patient age, allergic status, bronchodilator response, exhaled nitric oxide, and urinary leukotrienes as potential predictors of treatment response.
• Demonstrated the potential to predict which medication may be more effective for individual patients.

Conclusions:

• Treatment response to long-term asthma control medications is highly variable.
• Patient characteristics and specific biomarkers can aid in predicting individual treatment effectiveness.
• Personalized selection of asthma therapies at treatment initiation is now feasible, improving patient outcomes.